Comparative Safety and Effectiveness of Bevacizumab Biosimilars to Originator for the Treatment of Metastatic Colorectal Cancer
The demonstrated similarity in safety and effectiveness between bevacizumab biosimilars and originator bevacizumab provides further support for the use of and confidence in biosimilar products.
Authors
- Erind Dvorani (ORCID: https://orcid.org/0000-0001-8246-6151)
- Kelvin Chan (ORCID: https://orcid.org/0000-0002-2501-3057)
- Rebecca E. Mercer (ORCID: https://orcid.org/0000-0002-9264-7797)
- Scott Gavura (ORCID: https://orcid.org/0000-0002-8635-6889)
- Andrea Adamic
- Caroline Muñoz
- Jaclyn Beca (ORCID: https://orcid.org/0000-0001-8858-9566)
- Jessica Arias
Institutions
- Sunnybrook Health Science Centre (CA)
- Cancer Care Ontario (CA)
- Health Sciences Centre (CA)
- Institute for Clinical Evaluative Sciences (CA)
- Canadian Centre for Applied Research in Cancer Control (CA)
Publication Details
- Journal
- Journal of the National Comprehensive Cancer Network
- Published
- 2024-11-27
- DOI
- https://doi.org/10.6004/jnccn.2024.7053
- Citations
- 2
- Primary Topic
- Biosimilars and Bioanalytical Methods
- Type
- article
- Field-Weighted Citation Impact
- 0.48